

JC20 Rec'd PCT/PTO 0 3 AUG 2001

Sim & McBurney ~~5652~~


Patent and Trade-mark Agents

330 University Avenue
6th floor
Toronto, Canada
M5G 1R7
Telephone 416-595-1155
Fax 416-595-1163

MICHAEL I. STEWART
ROGER T. HUGHES, Q.C.
TONI POLSON ASHTON
JOHN H. WOODLEY
KENNETH D. MCKAY
TIMOTHY M. LOWMAN
STEPHEN M. LANE
ARTHUR B. RENAUD
STEPHEN J. PERRY
PATRICIA A. RAE
DAVID A. RUSTON
L.E. TRENT HORNE
LOLA A. BARTOSZEWICZ
THOMAS T. RIEDER
WARREN J. GALLOWAY
STEVEN L. NEMETZ
URSULA M. MCGUINNESS
ROBERT C.T. LIANG

SENIOR CONSULTANTS
PETER W. MCBURNEY
BRENDA L. BOARDMAN

TECHNICAL ASSISTANTS
KIMBERLY A. MCMANUS, PH.D.
PETER S. HARRISON, PH.D.
LESLEY M. MORRISON, B.Sc.MECH.
GEOFFREY B.C. DEKLEINE, M.Sc.(ENG.)
WENDY M. NOSS, B.A., L.L.B.



Please Quote
Our ref.

Your ref.

1038-1129 MIS/ac

Writer's Ext.

239

August 2, 2001

BY COURIER

The Commissioner of Patents
and Trademarks,
Washington, D.C. 20231,
U.S.A.

Dear Sirs:

Re: U.S. Patent Application No. 09/786,235
Filing Date : September 3, 1999
Applicant : Diane M. Gajewczyk et al
Group No.: ---
TREATMENT OF CERVICAL CANCER

Please find enclosed an Information Disclosure Statement and copies of the references listed therein with respect to each of the references cited in the specification, in the International Search Report received on the corresponding International application and in prior U.S. application No. 09/786,235. The items indicated by asterisks will follow shortly.

Yours very truly,

M.I. Stewart
Reg. No. 24,973

MIS/ac
Encl.



FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT	. ATTY. DOCKET NO 1038-1129 MIS:ac	SERIAL NO. 09/786,235
	APPLICANT Diane M. Gajewczyk et al	
	FILING DATE September 3, 1999	GROUP

U.S. PATENT DOCUMENTS


*INITIAL		DOCUMENT NO.	DATE	NAME	CLASS	SUBCL.	FILING DATE
		6,004,557	Dec. 1999	Edwards et al.			
		6,013,258	Jan. 2000	Urban et al.			
		5,744,133	April 1998	Lathe et al.			

FOREIGN PATENT DOCUMENTS

		DOCUMENT NO.	DATE	COUNTRY	CLASS	SUBCL.	TRANSLATION	
		WO 96/00583	Jan. 11/96				YES	NO
		WO 92/16636	Oct. 1/92					
		WO 97/05164	Feb. 13/97					
		WO 99/18995	Apr. 22/99					
		WO 93/24640	Dec. 9/93					

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

	**	1. Pisani P. et al., Estimated of the worldwide mortality from eighteen major cancers in 1985. Int. J. Cancer 1993 : 55 : 891-903
	**	2. Piver M.S., Handbood of gynecologic oncology. Boston: Little, Brown, 1996.
	**	3. Kurman R.J. et al., Interim guidelines for management of abnormal cervical cytology. The 1992 National Cancer Institute Workshop, IAMA 1994-271 : 1866-9.
	**	4. Bosch FX, et al., Prevalence of hman papillomavirus in cervical cancer a worlwide perspective. J. National Cancer Institute. 1995:87:796-802.
	**	5. Pecoraso G. et al., Differential effects of human papillomavires type 6, 16 and 18 DNAs ... USA, 1989 : 86, pp. 563-567.
	**	6. Shamanin C.G., et al., Specific types of human papillomavirus found in bening preliférations and carcinomas of the skin in immunosuppressed patients.Cancer Res. 1994:54, pp. 4610-3.
	**	7. Hilders C.G., et al., Association between HLA-expression and infiltration of immune cells in cervical carcinoma. Laboratories Investigation. 1993: 69, pp.651-619.
	**	8. Munger K., et al., Interactions of HPV E6 and E7 oncoproteins with tumour suppressor gene products. Cancer Surv. 1992:12, pp. 197-217.
	**	9. Dyson N., et al., The human papilloma virus-16 E7 oncoproteins with tumourScience : 1989:243, pp.934-937.
	**	10. Munger K., et al., Virol 1989 : 63, pp. 4417-4421.

<p>FORM PTO-1449</p> <p>U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE</p> <p>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</p> 	<p>ATTY. DOCKET NO 1038-1129 MIS:ac</p>	<p>SERIAL NO. 09/786,235</p>
	<p>APPLICANT Diane M. Gajewczyk et al</p>	
	<p>FILING DATE September 3, 1999</p>	<p>GROUP</p>

		11. Crook t., et al., Journal 1989 : 8, pp. 513-519
		12. Ressing M.E., et al., J. Immunol. 1995:154, pp. 5934-5943, XP002915422
	**	13. Kast W.M., et al., J., Immunol. 1994:152, pp. 3904-3912.
		14. Feltkamp M.C., et al., Immunol. 1993:23, pp. 2242-2249.
	**	15. Alexander M., et al., J. Obster. Gynecol 1996:175, pp. 1586-1593.
	**	16. Steller M.A., et al., Human Papillomavirus immuology and vaccine prospects.J. Natl. Cancer Inst. Monogr. 1996:21, pp. 145-148.
	**	17. Schiller J.T., et al., Papillomavirus vaccines: Current status and future prospects. Adv. Dermatol 1996:11, ppl355-80; discussion: 355-80; discusstion:381.
	**	18. Kimbauer R., et al., J. Virol 1993:67, pp. 6929-6936.
		19. Borysiewicz L.K. et al., Lancet 1996:347, pp. 1523-1527.
	**	20. Irvine K.R., et al., J. Immunol. 1995:154, pp. 4651-4657.
		21. WO 93/24640
		22. Tang et al., Nature 1992, 356: pp. 152-154.
		23. Furth et al., Analytical Biochemistry, 1992, 205, pp. 365-368.
		24. Munger K. et al., The EMBO Journal , 1989, vol. 8: 13, pp. 4099-4105. XP000611714.
		25. Sundaram P., et al., Vaccine 1998 : vol. 16, : 6, pp. 613-623. XPO002131646.
EXAMINER:		DATE CONSIDERED:

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if in conformance and not considered. Include copy of this form with next communication with applicant.

** Will follow shortly